OBJECTIVE: The current study examined the interactive effect of type 2 diabetes and Alzheimer disease (AD) risk factors on the rate of functional decline in cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative. METHODS: Participants underwent annual assessments that included the Functional Activities Questionnaire, an informant-rated measure of everyday functioning. Multilevel modeling, controlling for demographic variables and ischemic risk, examined the interactive effects of diabetes status (diabetes, n=69; no diabetes, n=744) and AD risk factors in the prediction of 5-year longitudinal change in everyday functioning. One model was run for each AD risk factor, including: objectively-defined subtle cognitive decline (Obj-SCD), and genetic susceptibility [apolipoprotein E ε4 (APOE ε4) as well as cerebrospinal fluid β-amyloid (Aβ), total tau (tau), and hyperphosphorylated tau (p-tau). RESULTS: The 3-way diabetes×AD risk factor×time interaction predicted increased rates of functional decline in models that examined Obj-SCD, APOE ε4, tau, and p-tau positivity, but not Aβ positivity. CONCLUSIONS: Participants with both diabetes and at least 1 AD risk factor (ie, Obj-SCD, APOE ε4, tau, and p-tau positivity) demonstrated faster functional decline compared with those without both risk factors (diabetes or AD). These findings have implications for early identification of, and perhaps earlier intervention for, diabetic individuals at risk for future functional difficulty.
OBJECTIVE: The current study examined the interactive effect of type 2 diabetes and Alzheimer disease (AD) risk factors on the rate of functional decline in cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative. METHODS:Participants underwent annual assessments that included the Functional Activities Questionnaire, an informant-rated measure of everyday functioning. Multilevel modeling, controlling for demographic variables and ischemic risk, examined the interactive effects of diabetes status (diabetes, n=69; no diabetes, n=744) and AD risk factors in the prediction of 5-year longitudinal change in everyday functioning. One model was run for each AD risk factor, including: objectively-defined subtle cognitive decline (Obj-SCD), and genetic susceptibility [apolipoprotein E ε4 (APOE ε4) as well as cerebrospinal fluid β-amyloid (Aβ), total tau (tau), and hyperphosphorylated tau (p-tau). RESULTS: The 3-way diabetes×AD risk factor×time interaction predicted increased rates of functional decline in models that examined Obj-SCD, APOE ε4, tau, and p-tau positivity, but not Aβ positivity. CONCLUSIONS:Participants with both diabetes and at least 1 AD risk factor (ie, Obj-SCD, APOE ε4, tau, and p-tau positivity) demonstrated faster functional decline compared with those without both risk factors (diabetes or AD). These findings have implications for early identification of, and perhaps earlier intervention for, diabetic individuals at risk for future functional difficulty.
Authors: Edmond Teng; Brian W Becker; Ellen Woo; David S Knopman; Jeffrey L Cummings; Po H Lu Journal: Alzheimer Dis Assoc Disord Date: 2010 Oct-Dec Impact factor: 2.703
Authors: Ozioma C Okonkwo; Michael L Alosco; H Randall Griffith; Michelle M Mielke; Leslie M Shaw; John Q Trojanowski; Geoffrey Tremont Journal: Arch Neurol Date: 2010-06
Authors: Katherine J Bangen; Alexa Beiser; Lisa Delano-Wood; Daniel A Nation; Melissa Lamar; David J Libon; Mark W Bondi; Sudha Seshadri; Philip A Wolf; Rhoda Au Journal: J Stroke Cerebrovasc Dis Date: 2013-04-17 Impact factor: 2.136
Authors: Amy J Jak; Mark W Bondi; Lisa Delano-Wood; Christina Wierenga; Jody Corey-Bloom; David P Salmon; Dean C Delis Journal: Am J Geriatr Psychiatry Date: 2009-05 Impact factor: 4.105
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Malin Degerman Gunnarsson; Martin Ingelsson; Kaj Blennow; Hans Basun; Lars Lannfelt; Lena Kilander Journal: Alzheimers Res Ther Date: 2016-06-06 Impact factor: 6.982
Authors: Kelsey R Thomas; Jessica R Osuna; Alexandra J Weigand; Emily C Edmonds; Alexandra L Clark; Sophia Holmqvist; Isabel H Cota; Christina E Wierenga; Mark W Bondi; Katherine J Bangen Journal: J Cereb Blood Flow Metab Date: 2020-07-02 Impact factor: 6.200
Authors: Kelsey R Thomas; Katherine J Bangen; Emily C Edmonds; Alexandra J Weigand; Kayla S Walker; Mark W Bondi; Douglas R Galasko Journal: Alzheimers Dement (Amst) Date: 2021-10-14
Authors: Madeleine L Werhane; Kelsey R Thomas; Katherine J Bangen; Alexandra J Weigand; Emily C Edmonds; Daniel A Nation; Erin E Sundermann; Mark W Bondi; Lisa Delano-Wood Journal: Front Aging Neurosci Date: 2021-10-25 Impact factor: 5.702
Authors: Kelsey R Thomas; Alexandra J Weigand; Lauren C Edwards; Emily C Edmonds; Katherine J Bangen; Gema Ortiz; Kayla S Walker; Mark W Bondi Journal: Alzheimers Res Ther Date: 2022-08-22 Impact factor: 8.823